Novartis: positive data in follicular lymphoma
(CercleFinance.com) - On Tuesday morning Novartis announced positive results from its Phase II ELARA trial of its Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma.
At the interim analysis, the global study met its primary endpoint of complete response rate (CRR), as assessed by independent review committee; no new safety signals were observed.
"ELARA trial findings will be included in regulatory submissions, with filing in the US anticipated in 2021, and the EU following. Results will be presented at an upcoming medical meeting," Novartis added.
Copyright (c) 2020 CercleFinance.com. All rights reserved.